Amgen confirmed on its fourth-quarter results call that it has resisted a request by the FDA to withdraw its drug for ANCA-associated vasculitis, Tavneos, from the US market. The FDA made its request ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results